• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of bmjBMJ helping doctors make better decisionsSearch bmj.comLatest content
BMJ. Mar 11, 2006; 332(7541): 563–564.
PMCID: PMC1397782

The burden of chronic kidney disease

Is rising rapidly worldwide
Rizwan A Hamer, specialist registrar
Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield S5 7AU

The number of patients with chronic kidney disease worldwide is rising markedly.1 In the United Kingdom, the annual incidence of end stage renal disease is around 100 per 1 000 000 population.2 This incidence has doubled over the past decade and is expected to continue to rise by 5-8% annually, but it remains well below the European average (around 135/1 000 000) and that of the United States (336/1 000 000).3

Disparities in the incidence of end stage renal disease within and between developed countries reflect racial and ethnic diversity. In the US, the annual incidence is 256/1 000 000 in white people compared with 982/1 000 000 in African-Americans.3 In Australia, the incidence in white people is comparable to that in the UK (94/1 000 000), but the incidence in aboriginals is 420/1 000 000.

The rise in end stage renal disease worldwide most probably reflects the global epidemic of type 2 diabetes and the ageing of the populations in developed countries, with a higher incidence in elderly people (the annual incidence in people over 65 in the UK is greater than 350/1 000 000,2 and in the US it is greater than 1200/1 000 000).3 The number of people with diabetes worldwide, currently around 154 million, is set to double within the next 20 years, and the increase will be most notable in the developing world, where the number of patients with diabetes is due to reach 286 million by 2025.4

The cost of treating patients with end stage renal disease is substantial and poses a great challenge to provision of care. In Europe, less than 0.1% of the population needs renal replacement therapy, which accounts for 2% of the healthcare budget. In the US, the annual cost of treatment for end stage renal disease is expected to reach $29bn (£17bn; €25bn) by 2010.1 Few countries will be able to meet these growing medical and financial demands; five countries—the US, Germany, Italy, Japan, and Brazil—with 12% of the world's population—already treat more than half of the world's people with end stage renal disease.5

More than 100 developing countries, together with a population in excess of 600 million, do not have any provision for renal replacement therapy.5 Consequently, more than a million people die every year worldwide from end stage renal disease. The huge disparity in the prevalence of this disease between the industrialised world and emerging nations reflects different priorities for health care and the inadequacy of resources allocated to renal replacement therapy.

Programmes to detect chronic kidney disease, linked to comprehensive primary and secondary prevention strategies, are needed urgently. Successful examples of such programmes have been shown in developed and developing countries; in the Netherlands, the prevention of renal and vascular end stage disease (PREVEND) screening programme detected albuminuria in around 6-7% of the population of the city of Groningen.6 In India's Chennai province7 and in the aboriginals of the northern Australian territories,8 the detection of chronic kidney disease and predisposing conditions such as diabetes and hypertension led to effective interventions. In Singapore, the national kidney foundation has launched a nationwide comprehensive screening and detection programme for chronic kidney disease.9

Patients with end stage renal disease comprise only a small percentage of people with chronic kidney disease.10 The total prevalence of chronic kidney disease may be 50 times that of treated end stage renal disease. In the US, up to 11% of the population (19 million) may have chronic kidney disease.10 Surveys in Australia, Europe, and Japan show that the prevalence of at least some degree of this chronic disease is 6-16%.11 Population based studies show that 6-7% of the population has albuminuria (or microalbuminuria) and around 0.6-0.7% proteinuria.11 The prevalence of chronic kidney disease is even higher (16%) when those at risk, including relatives of patients with the disease, are screened.12

Mass population screening for chronic kidney disease with tests such as urinalysis is neither practical nor likely to be successful or cost effective. Yet most clinical practice guidelines now recommend identifying those at risk—people with hypertension, diabetes, obesity, and other predisposing conditions or medicines as well as older people and relatives of patients with chronic kidney disease.13

Screening of urine samples with dipsticks for albuminuria and proteinuria is useful as long as it is confirmed by quantitative spot urine analysis for albumin:creatinine ratio or protein:creatinine ratio.13 These tests are more accurate than those based on the analysis of 24 hour urine collections in view of the inaccuracies of the latter. Serum creatinine is a readily available and reliable indicator of chronic kidney disease but it may be altered by a variety of factors, and renal function may be compromised considerably before serum creatinine concentrations rise. Reporting of serum creatinine is nowadays often linked to that of a calculated glomerular filtration rate.

Structured and well resourced primary prevention programmes based on reducing the risk factors for chronic kidney disease could make a big difference.11 Patients should be encouraged to give up smoking and to lose weight. Secondary prevention depends on tight control of blood pressure (to less than 130/80 mm Hg)9,14 and the use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers concomitantly to reduce proteinuria (to less than 1g/24 hours). Guidelines also recommend strict control of diabetes with an HbA1c level of around 7%.13 Statins may benefit patients with chronic kidney disease through preventing arteriosclerosis. Such a multifactorial approach to risk reduction may slow or even reverse declining renal function.15

Notes

Competing interests: None declared.

References

1. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002;13: 37-40. [PubMed]
2. Ansell D, Feest T, eds. UK renal registry report 2004. Bristol: UK Renal Registry, 2004.
3. United States Renal Data System (USRDS). 2004 annual report. Am J Kidney Dis 2005;45(suppl 1).
4. King H, Auburt RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21: 1414-31. [PubMed]
5. Lacson Jr E, Kuhlmann MK, Shah K, Yoshino M, Levin NW. Outcomes and economics of ESRF. In: El Nahas AM, ed. Kidney diseases in the developing world and ethnic minorities. New York: Taylor and Francis, 2005: 15-37.
6. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al,. Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001;249: 519-26. [PubMed]
7. Datta M, Mani MK. Community-based approach to prevention of chronic kidney disease: the Chennai experience. In: El Nahas AM, ed. Kidney diseases in the developing world and ethnic minorities. New York: Taylor and Francis, 2005: 395-409.
8. Hoy WE, Chennakesavan SK, McDonald SP, Cass A, Singh GR, Bertram JF, Hughson MD. Chronic kidney disease in Aboriginal Australians. In: El Nahas AM, ed. Kidney diseases in the developing world and ethnic minorities. New York: Taylor and Francis, 2005: 305-33.
9. Sylvia PB, Ramirez SIH, Stephen IHH, McClellan W. Taking a public health approach to the prevention of end-stage renal disease: the NKF Singapore program. Kidney Int 2003;(suppl 63): S61-5. [PubMed]
10. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis 2003;41: 1-12. [PubMed]
11. El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365: 331-40. [PubMed]
12. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen S-C, et al. Early detection of kidney disease in community settings. The kidney early evaluation programme (KEEP). Am J Kidney Dis 2003;42: 22-35. [PubMed]
13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39(suppl 1): 1-246. [PubMed]
14. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and anti-hypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(suppl 2): 1-290. [PubMed]
15. Ruggenenti P, Schieppati A, Perico N, Codreanu I, Peng L, Remuzzi G. Kidney prevention recipes for your office practice. Kidney Int 2005;67(suppl 94): S136-41. [PubMed]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Group
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...